시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 편두통 시장 보고서(2025년)
Migraine Global Market Report 2025
상품코드 : 1825463
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,516,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,419,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,322,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 편두통 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년까지 CAGR 3.5%로 확대되어 22억 5,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 병용요법의 채용, 편두통의 스크리닝 프로그램 증가, 흡연 습관의 유병률 증가, 편두통의 라이프 스타일 관리의 중요성의 인식 등에 기인하는 것으로 예측됩니다. 예측 기간의 주요 동향에는 편두통의 혁신적인 치료, 편두통의 표적 치료법 개발, 편두통의 진단 및 치료 진보, 편두통 관리를 위한 디지털 건강 기술이 포함됩니다.

향후 5년간의 성장률 3.5%라는 예측은 지난 예측으로부터 0.1% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 아일랜드와 스위스에서 조달하는 칼시토닌 유전자 관련 펩티드(CGRP) 억제제와 신경조절 기기의 비용을 증가시키고, 치료 접근을 제한하며, 신경과의 비용을 증가시킴으로써 미국을 억제할 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

편두통의 유병률 증가는 당분간 편두통 시장 확대에 박차를 가할 것으로 보입니다. 편두통은 한쪽 머리가 아픈 격렬한 두통으로 흠뻑 빠지는 강한 통증과 맥박 같은 감각이 특징입니다. 편두통 치료에는 통증 완화, 기능성 향상, 발작 빈도 및 중증도 감소, 생산성 향상, 편두통과 싸우는 사람들의 삶의 질 향상 등 몇 가지 이점이 있습니다. 예를 들어, 2023년 1월 영국 학술지 사이트 Nature Reviews Neurology가 보고한 바와 같이, 현재의 세계적인 추정에서는 편두통의 유병률은 14-15%이며, 전 세계의 장애와 함께 사는 연수(YLDs) 4.9%에 기여하고 있습니다. 따라서 편두통의 유병률 증가는 편두통 시장 성장의 중요한 촉진요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

A migraine is a neurological disorder characterized by recurrent and intense headaches, often accompanied by additional symptoms like nausea, vomiting, sensitivity to light (photophobia), and sensitivity to sound (phonophobia). These headaches are typically one-sided, pulsating, and can persist for several hours to a few days. The management of migraines involves a combination of strategies aimed at providing relief from immediate symptoms during an attack and preventing future migraine episodes.

Migraines come in two primary types are episodic and chronic. Chronic migraine is defined as experiencing headaches on at least 15 days per month for a minimum of three months, with at least 8 days each month featuring migraine-like symptoms. Treatment options include both preventive and abortive measures, involving various drug classes such as triptans, ergots, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The migraine market research report is one of a series of new reports from The Business Research Company that provides migraine market statistics, including the migraine industry global market size, regional shares, competitors with a migraine market share, detailed migraine market segments, market trends and opportunities and any further data you may need to thrive in the migraine industry. This migraine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The migraine market size has grown marginally in recent years. It will grow from $1.93 billion in 2024 to $1.97 billion in 2025 at a compound annual growth rate (CAGR) of 1.9%. The growth in the historic period can be attributed to increasing prevalence of migraines, growing awareness about migraine treatment, government initiatives, increasing prevalence of alcohol consumption, shifts in lifestyle.

The migraine market size is expected to see steady growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to adoption of combination therapies, growing number of screening programs for migraines, increasing prevalence of smoking habits, awareness of the importance of lifestyle management for migraine. Major trends in the forecast period include innovative treatments for migraines, development of targeted therapies for migraines, advancements in diagnosis and treatment of migraines, digital health technologies for migraine management.

The forecast of 3.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of calcitonin gene-related peptide (CGRP) inhibitors and neuromodulation devices sourced from Ireland and Switzerland, thereby limiting treatment access and elevating neurology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of migraines is poised to fuel the expansion of the migraine market in the foreseeable future. Migraines are severe headaches typically affecting one side of the head, characterized by intense throbbing pain or a pulsing sensation. Migraine treatments offer several advantages, including pain relief, improved functionality, reduced frequency and severity of attacks, enhanced productivity, and a better quality of life for individuals grappling with migraines. For instance, in January 2023, as reported by Nature Reviews Neurology, a UK-based journal website, the current global estimate indicates a migraine prevalence of 14-15%, contributing to 4.9% of the total global years lived with disability (YLDs). Hence, the increasing prevalence of migraines is a key driver of the migraine market's growth.

The increasing prevalence of stress is the driving force behind the growth of the migraine market. Stress represents the physiological and psychological response to challenging or demanding situations that individuals perceive as threatening, overwhelming, or beyond their ability to cope with effectively. Stress can act as a trigger for migraines, as it initiates the body's fight or flight response, leading to the release of stress hormones like cortisol and adrenaline. These hormones can induce rapid constriction and dilation of blood vessels, potentially contributing to changes in blood flow and vascular function associated with migraine attacks. For example, data from the American Psychiatric Association, a US-based professional organization of psychiatrists, indicated that over one in four (26%) Americans anticipated experiencing increased stress at the beginning of 2023, up from one in five (20%) the previous year. Consequently, the rising incidence of stress is fueling the expansion of the migraine market.

The prominent companies in the migraine market are dedicated to pioneering technological solutions like migraine lens technology to gain a competitive advantage. Migraine lens technology entails the development of specialized lenses tailored to alleviate discomfort in individuals with migraines and sensitivity to light. For example, in July 2023, Zenni Optical Inc., a US-based eyewear retailer, unveiled its groundbreaking innovation, the FL-41 migraine lenses. These lenses are engineered to provide relief to individuals suffering from light sensitivity due to migraines, post-concussion recovery, and other related conditions. Moreover, these lenses filter out a specific range of light that is known to trigger eye pain, thereby reducing the risk of migraines and even offering relief during active migraine episodes.

In October 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, completed the acquisition of Biohaven Pharmaceuticals Inc. for an estimated $11.6 billion. This strategic acquisition is part of Pfizer's efforts to enhance its portfolio and further its commitment to providing innovative treatment options for individuals suffering from migraines. Biohaven Pharmaceuticals Inc. is a US-based pharmaceutical company renowned for its development of migraine medications.

Major companies operating in the migraine market are Pfizer Inc., Johnson and Johnson Limited, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Limited, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Lannett Company Inc., Wockhardt Limited.

North America was the largest region in the migraine market in 2024. The regions covered in migraine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the migraine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The migraine market consists of revenues earned by entities by providing transcranial magnetic stimulation (TMS), relaxation therapies, stress management therapies, cognitive therapies and physical therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The migraine market also includes sales of prescription and over-the-counter (OTC) drugs, medical devices and alternative therapies for the treatment of migraines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Migraine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on migraine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for migraine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The migraine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Migraine Market Characteristics

3. Migraine Market Trends And Strategies

4. Migraine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Migraine Growth Analysis And Strategic Analysis Framework

6. Migraine Market Segmentation

7. Migraine Market Regional And Country Analysis

8. Asia-Pacific Migraine Market

9. China Migraine Market

10. India Migraine Market

11. Japan Migraine Market

12. Australia Migraine Market

13. Indonesia Migraine Market

14. South Korea Migraine Market

15. Western Europe Migraine Market

16. UK Migraine Market

17. Germany Migraine Market

18. France Migraine Market

19. Italy Migraine Market

20. Spain Migraine Market

21. Eastern Europe Migraine Market

22. Russia Migraine Market

23. North America Migraine Market

24. USA Migraine Market

25. Canada Migraine Market

26. South America Migraine Market

27. Brazil Migraine Market

28. Middle East Migraine Market

29. Africa Migraine Market

30. Migraine Market Competitive Landscape And Company Profiles

31. Migraine Market Other Major And Innovative Companies

32. Global Migraine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Migraine Market

34. Recent Developments In The Migraine Market

35. Migraine Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기